Physician profile
Jim Li
NPI 1053394106
$18,395.03
in general payments reported to CMS, 2019-2025
44 companies · $4,545 in 2025
The $4,545 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,441 · 2020: $1,301 · 2021: $2,184 · 2022: $1,833 · 2023: $1,847 · 2024: $3,244 · 2025: $4,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,136 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,136.14 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,722.09 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $1,704.79 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,401.19 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,353.81 | 2019-2025 | |
| Lilly USA, LLC | $1,332.34 | 2019-2024 | Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,057.33 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $895.45 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Sanofi-Aventis U.S. LLC | $837.33 | 2019-2023 | |
| Glaxosmithkline, LLC. | $811.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Cardinal Health 110 LLC | $800.00 | 2021-2025 | |
| Amarin Pharma, INC. | $784.76 | 2019-2023 | |
| Amgen INC. | $740.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Radius Health, INC. | $606.08 | 2019-2023 | Tymlos |
| Axsome Therapeutics, INC. | $512.50 | 2023-2025 | Auvelity |
| Daiichi Sankyo INC. | $460.36 | 2022-2025 | Injectafer |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.